Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes (Q38101982)

28 August 2017

Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes (English)

1 reference

28 August 2017

0 references

1 reference

1

1 reference

28 August 2017

Jesús Avila

2

1 reference

28 August 2017

1 May 2013

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

28 August 2017

1 reference

28 August 2017

13

1 reference

28 August 2017

5

1 reference

28 August 2017

495-503

1 reference

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease.

28 August 2017

1 reference

Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies

21 January 2018

1 reference

Glycogen synthase kinase-3--an overview of an over-achieving protein kinase

21 January 2018

1 reference

Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta

21 January 2018

1 reference

Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues

21 January 2018

1 reference

Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain

21 January 2018

1 reference

Neurological functions of the masterswitch protein kinase - gsk-3.

21 January 2018

1 reference

New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

21 January 2018

1 reference

A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health

21 January 2018

1 reference

Chemical rescue of cleft palate and midline defects in conditional GSK-3beta mice.

21 January 2018

1 reference

Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium

21 January 2018

1 reference

GSK-3beta is required for memory reconsolidation in adult brain

21 January 2018

1 reference

Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency

21 January 2018

1 reference

Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.

21 January 2018

1 reference

Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour

21 January 2018

1 reference

Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism

21 January 2018

1 reference

Abnormalities in brain structure and behavior in GSK-3alpha mutant mice

21 January 2018

1 reference

Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease

21 January 2018

1 reference

The inflammatory response to double stranded DNA in endothelial cells is mediated by NFκB and TNFα

21 January 2018

1 reference

GSK-3 is a master regulator of neural progenitor homeostasis

21 January 2018

1 reference

Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation

21 January 2018

1 reference

Functional significance of glycogen synthase kinase-3 regulation by serotonin

21 January 2018

1 reference

The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.

21 January 2018

1 reference

GSK3: a possible link between beta amyloid peptide and tau protein.

21 January 2018

1 reference

The GSK3 hypothesis of Alzheimer's disease

21 January 2018

1 reference

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

21 January 2018

1 reference

Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology?

21 January 2018

1 reference

Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta

21 January 2018

1 reference

Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease.

21 January 2018

1 reference

Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese.

21 January 2018

1 reference

Association of GSK3B with Alzheimer disease and frontotemporal dementia

21 January 2018

1 reference

Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease

21 January 2018

1 reference

Epistasis between tau phosphorylation regulating genes (CDK5R1 and GSK-3beta) and Alzheimer's disease risk

21 January 2018

1 reference

GSK3B polymorphisms alter transcription and splicing in Parkinson's disease

21 January 2018

1 reference

Role of tau protein in both physiological and pathological conditions.

21 January 2018

1 reference

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

21 January 2018

1 reference

Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity

21 January 2018

1 reference

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

21 January 2018

1 reference

Mechanisms of tau-induced neurodegeneration

21 January 2018

1 reference

Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

21 January 2018

1 reference

A beta oligomers - a decade of discovery

21 January 2018

1 reference

Extracellular tau is toxic to neuronal cells.

21 January 2018

1 reference

Extracellular tau promotes intracellular calcium increase through M1 and M3 muscarinic receptors in neuronal cells

21 January 2018

1 reference

Propagation of tau misfolding from the outside to the inside of a cell.

21 January 2018

1 reference

Transmission and spreading of tauopathy in transgenic mouse brain

21 January 2018

1 reference

Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model

21 January 2018

1 reference

Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

21 January 2018

1 reference

Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders

21 January 2018

1 reference

Recent developments in tau-based therapeutics for neurodegenerative diseases

21 January 2018

1 reference

Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease

21 January 2018

1 reference

Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci.

21 January 2018

1 reference

GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers

21 January 2018

1 reference

Regulation of neuronal cytoskeleton by lysophosphatidic acid: role of GSK-3.

21 January 2018

1 reference

Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila

21 January 2018

1 reference

Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event

21 January 2018

1 reference

Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo

21 January 2018

1 reference

GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity.

21 January 2018

1 reference

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

21 January 2018

1 reference

Alzheimer's disease is a synaptic failure

21 January 2018

1 reference

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior

21 January 2018

1 reference

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides

21 January 2018

1 reference

Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing

21 January 2018

1 reference

Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100.

21 January 2018

1 reference

GSK-3α/β kinases and amyloid production in vivo

21 January 2018

1 reference

Presenilin 1 regulates beta-catenin-mediated transcription in a glycogen synthase kinase-3-independent fashion

21 January 2018

1 reference

Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate

21 January 2018

1 reference

PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations

21 January 2018

1 reference

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation.

21 January 2018

1 reference

Protein phosphorylation and APP metabolism

21 January 2018

1 reference

The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice.

21 January 2018

1 reference

Alphabeta hinders nuclear targeting of AICD and Fe65 in primary neuronal cultures

21 January 2018

1 reference

Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway.

21 January 2018

1 reference

Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling

21 January 2018

1 reference

Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-β precursor protein

21 January 2018

1 reference

Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes

21 January 2018

1 reference

Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease

21 January 2018

1 reference

Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies

21 January 2018

1 reference

Glycogen synthase kinase-3 inhibition is integral to long-term potentiation.

21 January 2018

1 reference

LTP inhibits LTD in the hippocampus via regulation of GSK3beta

21 January 2018

1 reference

A systematic investigation of the protein kinases involved in NMDA receptor-dependent LTD: evidence for a role of GSK-3 but not other serine/threonine kinases

21 January 2018

1 reference

Glycogen synthase kinase 3 regulates N-methyl-D-aspartate receptor channel trafficking and function in cortical neurons.

21 January 2018

1 reference

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

21 January 2018

1 reference

The role of GSK-3 in synaptic plasticity.

21 January 2018

1 reference

Regulation of AMPA receptor trafficking and function by glycogen synthase kinase 3.

21 January 2018

1 reference

A pivotal role of GSK-3 in synaptic plasticity.

21 January 2018

1 reference

Regulation of GABAergic synapse formation and plasticity by GSK3beta-dependent phosphorylation of gephyrin.

21 January 2018

1 reference

N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation.

21 January 2018

1 reference

Calpain regulates N-terminal interaction of GSK-3β with 14-3-3ζ, p53 and PKB but not with axin

21 January 2018

1 reference

Early intraneuronal Abeta deposition in the hippocampus of APP transgenic mice

21 January 2018

1 reference

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

21 January 2018

1 reference

Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β.

21 January 2018

1 reference

TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth

21 January 2018

1 reference

Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models

21 January 2018

1 reference

Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation

21 January 2018

1 reference

Deciphering the molecular basis of memory failure in Alzheimer's disease

21 January 2018

1 reference

The cell biology of synaptic plasticity.

21 January 2018

1 reference

Long-term depression in the CNS.

21 January 2018

1 reference

GSK-3β and memory formation

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.13.39

1 reference

28 August 2017

1 reference

PubMed ID

23621307